ライフサイエンスコーパス: lymphocytic leukaemia

1 atients with chronic granulocytic or chronic lymphocytic leukaemia.

2 nib has transformed the treatment of chronic lymphocytic leukaemia.

3 in patients with previously treated chronic lymphocytic leukaemia.

4 patients with relapsed or refractory chronic lymphocytic leukaemia.

5 patients with relapsed or refractory chronic lymphocytic leukaemia.

6 ted in familial glioma, melanoma and chronic lymphocytic leukaemia.

7 patients with relapsed or refractory chronic lymphocytic leukaemia.

8 patients with relapsed or refractory chronic lymphocytic leukaemia.

9 urther advance treatment of del(17p) chronic lymphocytic leukaemia.

10 tuximab 500 mg/m(2) in patients with chronic lymphocytic leukaemia.

11 with relapsed or refractory del(17p) chronic lymphocytic leukaemia.

12 hysically fit patients with advanced chronic lymphocytic leukaemia.

13 iagnostic criteria for T cell large granular lymphocytic leukaemia.

14 re-induction treatment for relapsed chronic lymphocytic leukaemia.

15 fficacy as monotherapy in refractory chronic lymphocytic leukaemia.

16 cohesion, is recurrently mutated in chronic lymphocytic leukaemia.

17 atients aged 65 years and older with chronic lymphocytic leukaemia.

18 e and are found in cancers including chronic lymphocytic leukaemia.

19 g modified International Workshop on Chronic Lymphocytic Leukaemia 2008 criteria.

20 lation per International Workshop on Chronic Lymphocytic Leukaemia 2008 response criteria modified fo

21 older with a documented diagnosis of chronic lymphocytic leukaemia according to the 2008 Internationa

22 patients with relapsed or refractory chronic lymphocytic leukaemia (according to the 2008 Modified In

23 patients with relapsed or refractory chronic lymphocytic leukaemia achieved an overall response.

24 Treatment-naive fit patients with chronic lymphocytic leukaemia (aged 33-81 years) without del(17p

25 patients with refractory and relapsed acute lymphocytic leukaemia (ALL) is poor.

26 se series of patients with acute and chronic lymphocytic leukaemia and B-cell lymphomas, but feasibil

27 patients with relapsed or refractory chronic lymphocytic leukaemia and could allow some patients to m

28 he treatment of patients with del17p chronic lymphocytic leukaemia and has been incorporated into tre

29 pecific for tumour cells but primary chronic lymphocytic leukaemia and mantle cell lymphoma (MCL) cel

30 GH and AID off-target sites in human chronic lymphocytic leukaemia and mantle cell lymphoma cell line

31 from two different types of cancer, chronic lymphocytic leukaemia and medulloblastoma, we conduct a

32 ious triumphs, for instance in cure of acute lymphocytic leukaemia and other childhood cancers, Hodgk

33 ow become the standard treatment for chronic lymphocytic leukaemia and the basis for new protocols th

34 , 2012, we enrolled 29 patients with chronic lymphocytic leukaemia and two patients with small lympho

35 , is frequently rearranged in B-cell chronic lymphocytic leukaemia, and contains the DAOA locus assoc

36 sion body myositis and T cell large granular lymphocytic leukaemia are rare diseases involving pathog

37 with del(17p) relapsed or refractory chronic lymphocytic leukaemia (as defined by 2008 Modified Inter

38 malignant cells from patients with B-chronic lymphocytic leukaemia (B-CLL) and of normal B lymphocyte

39 Primary B cells from B cell chronic lymphocytic leukaemia (B-CLL) were resistant to the nove

40 ATM gene in sporadic cases of B-cell chronic lymphocytic leukaemia (B-CLL).

41 The molecular classification of chronic lymphocytic leukaemia based on B-cell receptor immunoglo

42 nt-line therapy in fit patients with chronic lymphocytic leukaemia, but bendamustine and rituximab is

43 molecule BCL2 inhibitor that induces chronic lymphocytic leukaemia cell apoptosis.

44 y induce apoptosis in MOLT-4 and Jurkat E6 T lymphocytic leukaemia cells following intracytoplasmic d

45 hrough whole-exome sequencing of 538 chronic lymphocytic leukaemia (CLL) and matched germline DNA sam

46 About 30% of cases of chronic lymphocytic leukaemia (CLL) carry quasi-identical B-cell

47 togenetics represent the majority of chronic lymphocytic leukaemia (CLL) cases, yet have relatively f

48 nds play a critical role in enabling chronic lymphocytic leukaemia (CLL) cells access to protective m

49 A key feature of chronic lymphocytic leukaemia (CLL) cells is overexpressed prote

50 ent genome-wide association study of chronic lymphocytic leukaemia (CLL) has identified a susceptibil

51 treatment of patients with relapsed chronic lymphocytic leukaemia (CLL) in combination with rituxima

52 Chronic lymphocytic leukaemia (CLL) is a clonal disorder of matu

53 Chronic lymphocytic leukaemia (CLL) is a frequent B-cell maligna

54 Chronic lymphocytic leukaemia (CLL) is a frequent disease in whi

55 Chronic lymphocytic leukaemia (CLL) is a heterogeneous disease;

56 Chronic lymphocytic leukaemia (CLL) is a malignant haematologica

57 Chronic lymphocytic leukaemia (CLL) is an incurable and chronic

58 Chronic lymphocytic leukaemia (CLL) is characterized by substant

59 Pathogenesis of chronic lymphocytic leukaemia (CLL) is contingent upon antigen r

60 Chronic lymphocytic leukaemia (CLL) is the most common B-cell ma

61 Chronic lymphocytic leukaemia (CLL) is the most common clonal B-

62 Chronic lymphocytic leukaemia (CLL) results from the accumulatio

63 Several chronic lymphocytic leukaemia (CLL) susceptibility loci have bee

64 Neoplastic cells from patients with chronic lymphocytic leukaemia (CLL) were cultured in the presenc

65 the quality of life of patients with chronic lymphocytic leukaemia (CLL) who do not require systemic

66 Patients with chronic lymphocytic leukaemia (CLL) with TP53 aberrations respon

67 ion factor that has been linked with chronic lymphocytic leukaemia (CLL), but its functions in CLL ma

68 In chronic lymphocytic leukaemia (CLL), mutation/deletion of TP53 i

69 nces in the proportion of cases with chronic lymphocytic leukaemia (CLL)-phenotype MBL and CD5-negati

70 treatment for patients with advanced chronic lymphocytic leukaemia (CLL).

71 re associated with poor prognosis in chronic lymphocytic leukaemia (CLL).

72 in patients with advanced stages of chronic lymphocytic leukaemia (CLL).

73 e of the neoplastic B lymphocytes in chronic lymphocytic leukaemia (CLL).

74 elapsed or refractory B-cell NHL and chronic lymphocytic leukaemia (CLL).

75 al evolution, and chemoresistance in chronic lymphocytic leukaemia (CLL).

76 an effective treatment for relapsed chronic lymphocytic leukaemia (CLL).

77 d genome-wide association studies of chronic lymphocytic leukaemia (CLL, N = 1,842), Hodgkin lymphoma

78 some 17p (del[17p]) in patients with chronic lymphocytic leukaemia confers very poor prognosis when t

79 lymphoma, rheumatoid arthritis, and chronic lymphocytic leukaemia (Europe only); multiple sclerosis

80 ong treatment-free survival (TFS) in chronic lymphocytic leukaemia have been investigated, most have

81 Patients with 17p deletion (del17p) chronic lymphocytic leukaemia have poor responses and survival a

82 rall survival in young patients with chronic lymphocytic leukaemia; however, its application in elder

83 al for treatment-naive patients with chronic lymphocytic leukaemia in 109 centres in 16 countries.

84 130 centres in 24 countries who had chronic lymphocytic leukaemia in complete or partial remission a

85 nt groups (one [2%] patient with fatal acute lymphocytic leukaemia in the lenalidomide group and one

86 second-line therapy in patients with chronic lymphocytic leukaemia is unknown.

87 ) and 2008 International Workshop on Chronic Lymphocytic Leukaemia (IWCLL) criteria.

88 strategies in patients with relapsed chronic lymphocytic leukaemia, notably in the present era of tar

89 ears) with previously treated del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma rece

90 Most patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma rela

91 least 65 years, and had symptomatic chronic lymphocytic leukaemia or small lymphocytic lymphoma requ

92 onsisted of 144 patients with del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma who

93 (>/=18 years of age) who had active chronic lymphocytic leukaemia or small lymphocytic lymphoma with

94 st difficult subset of patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.

95 d or refractory patients with del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma.

96 in patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma.

97 untreated patients with symptomatic chronic lymphocytic leukaemia, or small lymphocytic lymphoma is

98 sistance in serial samples from five chronic lymphocytic leukaemia patients.

99 with relapsed or refractory del(17p) chronic lymphocytic leukaemia, providing a new therapeutic optio

100 Previous studies of patients with chronic lymphocytic leukaemia reported high response rates to fl

101 777 patients with chronic lymphocytic leukaemia requiring treatment were randomly

102 8 years) with relapsed or refractory chronic lymphocytic leukaemia requiring treatment who had measur

103 T-cell large granular lymphocytic leukaemia (T-LGL) is a lymphoproliferative d

104 y of the 2000 mg dose established in chronic lymphocytic leukaemia, the study was amended on Dec 9, 2

105 rituximab should allow patients with chronic lymphocytic leukaemia to receive clinical benefit from t

106 dverse events (four pneumonia, three chronic lymphocytic leukaemia, two Richter's syndrome, two sepsi

107 and Sept 29, 2015, 314 patients with chronic lymphocytic leukaemia were enrolled and randomly assigne

108 patients with relapsed or refractory chronic lymphocytic leukaemia were enrolled from 15 sites across

109 ged 18 years or older with untreated chronic lymphocytic leukaemia were randomly assigned, via an int

110 8 previously untreated patients with chronic lymphocytic leukaemia were screened for the study; 379 (

111 Patients were eligible if they had chronic lymphocytic leukaemia; were aged 18 years or older; had

112 solidation strategy in patients with chronic lymphocytic leukaemia, which could improve survival.

113 Treatment for patients with chronic lymphocytic leukaemia who are elderly or who have comorb

114 tients with recurrent or progressive chronic lymphocytic leukaemia who are in complete or partial res

115 afety of venetoclax in patients with chronic lymphocytic leukaemia who are refractory to or relapse d

116 gression in first-line patients with chronic lymphocytic leukaemia who do not achieve minimal residua

117 e treatment option for patients with chronic lymphocytic leukaemia who do not have access to kinase i

118 ith previously untreated progressive chronic lymphocytic leukaemia who had an Eastern Cooperative Onc

119 ile in treatment-naive patients with chronic lymphocytic leukaemia who were elderly or had comorbidit

120 patients with relapsed or refractory chronic lymphocytic leukaemia whose disease progressed during or

121 with immunophenotypically confirmed chronic lymphocytic leukaemia with active disease, who responded

122 ual disease identifies patients with chronic lymphocytic leukaemia with poor outcome after first-line